Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms, Plasma Cell × Maintenance × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 3 Smoldering Multiple Myeloma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Leukemia, Promyelocytic, Acute 1 Leukemia, Myeloid, Acute 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 17 Melphalan 13 Thalidomide 9 Bortezomib 9 Cyclophosphamide 8 Prednisone 6 Lenalidomide 6 Filgrastim 6 Epoetin Alfa 5 Doxorubicin 5 Vincristine 4 Zoledronic Acid 3 Peripheral Blood Stem Cell Transplantation 3 Idarubicin 3 pomalidomide 2 carfilzomib 2 Vorinostat 2 Radiotherapy 2 Interferon-alpha 2 Granulocyte Colony-Stimulating Factor 2 Early Intervention, Educational 2 Darbepoetin alfa 2 Carmustine 2 Calcium Dobesilate 2 Busulfan 2 valspodar 1 sargramostim 1 oblimersen 1 holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid) 1 fludarabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01554852 2018-06-11

Myeloma XI

University of Leeds

Phase 3 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡